Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 14, 2026, 7:28 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 625–648 of 3,919 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Cancer, Prostate Clear all

Conditions: Prostate Cancer, Prostatic Neoplasms
Interventions: High-Intensity Interval Training Exercise Program; Behavioral
Lead sponsor: Fred Hutchinson Cancer Center; Other
Eligibility: 18 Years and older · Male only
Enrollment: 68 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 4
States / cities: Boston, Massachusetts • Seattle, Washington

Conditions: Prostate Cancer
Interventions: Mindfulness Program; Behavioral
Lead sponsor: Northwestern University; Other
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2018
U.S. locations: 1
States / cities: Evanston, Illinois

Conditions: Prostate Carcinoma
Interventions: Focus group, Clinician Interviews, Intervention testing, Survey, Follow-up Interview, Virtual Health Intervention; Other
Lead sponsor: Mayo Clinic; Other
Eligibility: Up to 80 Years
Enrollment: 38 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2026
U.S. locations: 1
States / cities: Jacksonville, Florida

Conditions: Metastatic Prostate Cancer, Castration-resistant Prostate Cancer, Metastatic Castration-resistant Prostate Cancer
Interventions: 177Lu-PSMA-617, Niraparib abiraterone acetate, Prednisone; Drug
Lead sponsor: Baptist Health South Florida; Other
Eligibility: 18 Years and older · Male only
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Prostate Cancer
Interventions: flotufolastat F 18, Relugolix 120 MG, Serum PSA and Testosterone; Diagnostic Test · Drug
Lead sponsor: Urology Clinics of North Texas; Network
Eligibility: Male only
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Prostate Cancer
Interventions: High Dose brachytherapy boost, External beam radiotherapy; Radiation
Lead sponsor: Radiation Therapy Oncology Group; Network
Eligibility: 18 Years and older · Male only
Enrollment: 129 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2016
U.S. locations: 12
States / cities: Burbank, California • Inglewood, California • Sacramento, California + 9 more

Conditions: Prostate Cancer (Adenocarcinoma), Adenocarcinoma of the Prostate, Metastatic Castration-resistant Prostate Cancer (mCRPC), Metastatic Hormone-Sensitive Prostate Cancer (mHSPC), Biochemical Recurrence (BCR), High-Risk Localized Prostate Cancer
Interventions: RYZ711, PSMA PET/CT; Drug · Diagnostic Test
Lead sponsor: RayzeBio, Inc.; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 116 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Omaha, Nebraska

Conditions: Solid Malignancies, Non-Hodgkin's Lymphoma
Interventions: AQ4N; Drug
Lead sponsor: Novacea; Industry
Eligibility: 18 Years and older
Enrollment: 45 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2004
U.S. locations: 2
States / cities: The Bronx, New York • San Antonio, Texas

Conditions: Cancer of Prostate
Interventions: leuprolide acetate; Drug
Lead sponsor: San Bernardino Urological Associates Medical Group Inc; Other
Eligibility: 18 Years and older · Male only
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2005
U.S. locations: 1
States / cities: San Bernardino, California

Conditions: Prostate Cancer
Interventions: ZD4054 (Zibotentan), Docetaxel, Placebo; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 44 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2009
U.S. locations: 3
States / cities: Buffalo, New York • Greenville, South Carolina • Nashville, Tennessee

Conditions: Hormone Refractory Prostate Cancer, Recurrent Prostate Cancer
Interventions: cediranib maleate, dasatinib; Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older · Male only
Enrollment: 22 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2014
U.S. locations: 5
States / cities: Peoria, Illinois • Springfield, Illinois • Fort Wayne, Indiana + 2 more

Conditions: Recurrent Prostate Carcinoma, Stage I Prostate Cancer AJCC v7, Stage IIA Prostate Cancer AJCC v7, Stage IIB Prostate Cancer AJCC v7, Stage III Prostate Cancer AJCC v7
Interventions: Akt Inhibitor MK2206, Bicalutamide, Clinical Observation, Laboratory Biomarker Analysis; Drug · Other
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older · Male only
Enrollment: 108 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2026
U.S. locations: 192
States / cities: Palo Alto, California • Aurora, Colorado • Boulder, Colorado + 139 more

Conditions: Osteoporosis, Prostate Cancer
Interventions: cholecalciferol, calcium gluconate, zoledronic acid; Dietary Supplement · Drug
Lead sponsor: Northwestern University; Other
Eligibility: 18 Years and older · Male only
Enrollment: 53 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2008
U.S. locations: 3
States / cities: Chicago, Illinois

Conditions: Prostate Cancer
Interventions: PSMA-Targeted [In-111]-Labeled Trillium Compound, PTI-122; Drug
Lead sponsor: Ratio Therapeutics, Inc.; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 23 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 4
States / cities: Miami, Florida • Glen Burnie, Maryland • Omaha, Nebraska + 1 more

Conditions: Cancer-related Fatigue, Breast Cancer, Prostate Cancer
Interventions: Telehealth Exercise Program; Behavioral
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 18 Years to 89 Years
Enrollment: 134 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2030
U.S. locations: 2
States / cities: Aurora, Colorado • Missoula, Montana

Conditions: Prostatic Neoplasm
Interventions: EZN-4176; Drug
Lead sponsor: Enzon Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2013
U.S. locations: 1
States / cities: New York, New York

Conditions: Prostate Cancer
Interventions: cholecalciferol, placebo; Drug · Other
Lead sponsor: Medical University of South Carolina; Other
Eligibility: 19 Years to 90 Years · Male only
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2015
U.S. locations: 2
States / cities: Charleston, South Carolina

Conditions: Bone Metastases, Multiple Myeloma
Interventions: ExAblate MRfFUS, Sham; Device
Lead sponsor: InSightec; Industry
Eligibility: 18 Years to 100 Years
Enrollment: 147 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2012
U.S. locations: 8
States / cities: La Jolla, California • Stanford, California • Boca Raton, Florida + 5 more

Conditions: Prostate Cancer
Interventions: external beam radiation therapy, brachytherapy, questionnaires; Radiation · Behavioral
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 45 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2023
U.S. locations: 6
States / cities: Basking Ridge, New Jersey • Commack, New York • Harrison, New York + 3 more

Conditions: Prostate Cancer, Castration-Resistant Prostate Cancer
Interventions: Transdermal Testosterone, Standard of Care, Enzalutamide; Drug
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 18 Years to 100 Years · Male only
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2025
U.S. locations: 1
States / cities: Aurora, Colorado

Conditions: Prostate Cancer Metastatic
Interventions: Telaglenastat, Talazoparib; Drug
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years and older · Male only
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Prostate Cancer
Interventions: Enzalutamide, Active Surveillance; Drug · Other
Lead sponsor: Astellas Pharma Global Development, Inc.; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 227 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2020
U.S. locations: 50
States / cities: Birmingham, Alabama • Homewood, Alabama • Tucson, Arizona + 41 more

Conditions: Prostate Adenocarcinoma
Interventions: cabozantinib; Drug
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years and older · Male only
Enrollment: 34 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2013
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Aggressive Variant Prostate Carcinoma
Interventions: Zanzalintinib; Drug
Lead sponsor: Deepak Kilari; Other
Eligibility: 18 Years and older · Male only
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 1
States / cities: Milwaukee, Wisconsin

Search by objective public record fields.

Exercise for Tumor Suppressive Impact in Men With Prostate Cancer at High-Risk of Progression on Active Surveillance: The REMOVE Trial

Mindfulness Online for Symptom Alleviation and Improvement in Cancer of the Prostate

iCCaRE Consortium Pilot Project 1: Feasibility of a Point of Prostate Cancer Diagnosis Intervention for Newly Diagnosed Black Men

177Lu-PSMA, Niraparib/AA Plus Prednisone for Prostate Cancer

Pilot Study: Androgen Deprivation Therapy Impact on PSMA-PET Sensitivity in Prostatectomy Staging

Radiation Therapy in Treating Patients With Stage II or Stage III Prostate Cancer

RYZ711 Diagnostic Platform Study

Chemotherapy for Patients With Advanced Solid Tumors or Non-Hodgkin's Lymphoma

A Six-Month, Open-Label, Crossover Study Of the Maintenance Of Serum Testosterone And PSA Suppression After Switching Between Lupron 22.5 Mg And Eligard 22.5 Mg Or Zoladex 10.8 Mg And Eligard 22.5 Mg In Patients With Advanced Prostate Cancer

Phase I Study of ZD4054 (Zibotentan) and Docetaxel in Patients With Metastatic HRPC

Cediranib Maleate With or Without Dasatinib in Patients With HRPC-Resistant to Treatment With Docetaxel

Bicalutamide With or Without Akt Inhibitor MK2206 in Treating Patients With Previously Treated Prostate Cancer

Zolendronate for the Prevention of Bone Loss in Men w/ Prostate CA on Long-Term Androgen Deprivation

Exploratory PK and Imaging Study of PSMA-Targeted Trillium Compounds and PTI-122 in Metastatic Prostate Cancer

Telehealth Exercise Program Evaluating Fatigue and Physical Function in Rural Cancer Survivors

A Phase 1a/1b Study to Evaluate the Safety of EZN-4176, in Adult Patients With Castration-Resistant Prostate Cancer

Vitamin D and Prostate Cancer: A Clinical Study Enrolling Subjects Undergoing Prostatectomy

ExAblate (MRgFUS) Treatment of Metastatic Bone Tumors for the Palliation of Pain

Radiation Therapy in Combination With Brachytherapy for Clinically Localized, Intermediate Risk Prostate Cancer

Testosterone Therapy in Castration Resistant Prostate Cancer

Telaglenastat + Talazoparib In Prostate Cancer

A Randomized Study of Enzalutamide in Patients With Localized Prostate Cancer Undergoing Active Surveillance

Cabozantinib (XL184) in Men With Castrate-Resistant Prostate Cancer

Zanzalintinib in Men With Aggressive Variant Prostate Cancer